Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120686 | 1.00 | ALPL (0.48) | ALPLALPIKMT2AALDH1A1LMNA | |
| SCHEMBL23723550 | 0.93 | ALPL (0.48) | ALPLALPIKMT2AALDH1A1LMNA | |
| SCHEMBL30120689 | 0.93 | ALPL (0.48) | ALPLALPIKMT2AALDH1A1LMNA | |
| SCHEMBL30120732 | 0.90 | KMT2A (0.49) | ALPLALPIKMT2AALDH1A1LMNA | |
| SCHEMBL23723611 | 0.90 | KMT2A (0.49) | ALPLALPIKMT2AALDH1A1LMNA | |
| SCHEMBL23723504 | 0.90 | ALDH1A1 (0.54) | ALPLKMT2AALDH1A1LMNATDP1 | |
| SCHEMBL30132113 | 0.90 | ALDH1A1 (0.54) | ALPLKMT2AALDH1A1LMNATDP1 | |
| SCHEMBL26524078 | 0.89 | ALPL (0.46) | ALPLALPIKMT2AALDH1A1LMNA | |
| SCHEMBL23723549 | 0.88 | MEN1 (0.45) | ALPLKMT2AALDH1A1LMNATDP1 | |
| SCHEMBL23723652 | 0.88 | ALDH1A1 (0.46) | ALPLALPIKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | ALPL 653/4885ALPI 902/4885KMT2A 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.